Oct 28 2008, 6:01 AM EST
News source: Business Wire
Centinel Spine, Inc. announced today that it has initiated US
Alpha Site evaluation of the STALIF C(TM) NO PROFILE(TM) Stand Alone
Cervical IBF Device for single level use in the treatment of cervical
degenerative disc disease. The Company expects STALIF C(TM) to be
available in early 2009, enabling spine surgeons to use the technology
as an IBF device without supplementary fixation.
This evaluation is expected to take from one to two months and
will determine when Centinel Spine will initiate the US sales launch
of the STALIF C(TM) device in 2009. "The Alpha Site evaluation of the
STALIF C(TM) is an important step of many steps needed for bringing
this unique device to the US spine fusion market," said John J.
Viscogliosi, Chairman & CEO of Centinel Spine, Inc. "We are pleased to
reach a new milestone in the commercialization of STALIF C(TM), which
we look forward to adding to our product portfolio."
About Centinel Spine, Inc.
Centinel Spine, Inc. is a leading global medical device company
providing the PEEK-OPTIMA(R) STALIF TT(TM) and STALIF C(TM)
technologies for Stand Alone Interbody Fusion (IBF) procedures. The
STALIF TT(TM) and STALIF C(TM) technologies have been used in nearly
10,000 patients worldwide. The Company is dedicated to "Transforming
Spine Surgeons' Ideas into Tomorrow's Technology." For more
information, visit the Company website: www.centinelspine.com
ADVERTISEMENT
INTERVIEW:
NEW PROGNOSTIC GENETIC TEST FOR ADOLESCENT SCOLIOSIS - Interview with Dr. Baron Lonner, director of Scoliosis and Spine Associates
...MORE
NewsArticles BlogsADVERTISEMENT
Subscribe to RSS
Email
Print
Share
More News
Listen
Save
Comment
View All